Inflammatory Bowel Diseases

Skip Navigation LinksHome > December 2010 - Volume 16 - Issue 12 > Safety of infliximab in Crohn's disease: A large single‐cent...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21290
Original Clinical Articles: Safety of Infliximab in CD: Original Article

Safety of infliximab in Crohn's disease: A large single‐center experience

Hamzaoglu, H. MD1,*; Cooper, J. MD1; Alsahli, M. MD1; Falchuk, K. R. MD1; Peppercorn, M. A. MD1; Farrell, R. J. MD1

Collapse Box


Background:: The aim of this study was to evaluate the short‐ and long‐term safety experience of infliximab treatment in patients with Crohn's disease (CD) in clinical practice.

Methods:: The medical records of 297 consecutive patients with CD treated with infliximab at the Beth Israel Deaconess Medical Center were reviewed for demographic features and adverse events.

Results:: The 297 patients received a total of 1794 infusions. Patients received a median of four infusions and had a median follow‐up of 14.3 months. Forty‐four patients (15%) experienced a serious adverse event, requiring the infusion to be stopped in 33 patients (11%). Acute infusion reactions occurred in 18 patients (6%) including respiratory problems in 10 patients (3%) and an anaphylactoid reaction in 1 patient (0.3%). Serum sickness‐like disease occurred in one patient (0.3%) and three patients (1%) developed drug‐induced lupus. One patient developed a probable new demyelination disorder. Eight patients (2.7%), all of whom were on concurrent immunosuppressants, developed a serious infection, one resulting in fatal sepsis. Six patients (2%) developed malignancies including two lymphomas and two skin cancers. A total of four (1.3%) deaths were observed (median age 72.5 years); two due to gastrointestinal bleeding, one due to sepsis, and one due to malignancy.

Conclusions:: While short‐ and long‐term infliximab therapy was generally well tolerated, serious adverse events occurred in 15% of patients including drug‐induced lupus, fatal sepsis, and malignancy. Concomitant immunosuppressants were significantly associated with infections and deaths, particularly among elderly patients. (Inflamm Bowel Dis 2010)

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.